Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

被引：21

作者：

Berdeja, Jesus G. ^{[1
]}

Hernandez-Ilizaliturri, Francisco ^{[2
]}

Chanan-Khan, Asher ^{[3
]}

Patel, Manish ^{[4
,5
]}

Kelly, Kevin R. ^{[6
]}

Running, Kelli L. ^{[7
]}

Murphy, Mary ^{[7
]}

Guild, Robin ^{[7
]}

Carrigan, Christina ^{[7
]}

Ladd, Sharron ^{[7
]}

Wolf, Beni B. ^{[7
]}

O'Leary, James J. ^{[7
]}

Ailawadhi, Sikander ^{[8
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[3] Mayo Clin, Dept Hematol Oncol, Jacksonville, FL 32224 USA

[4] Sarah Cannon Res Inst, Sarasota, FL USA

[5] Florida Canc Specialists, Sarasota, FL USA

[6] Univ Texas Hlth Sci Ctr San Antonio, CTRC, Inst Drug Dev, San Antonio, TX 78229 USA

[7] ImmunoGen Inc, Waltham, MA USA

[8] Univ Calif Los Angeles, Div Hematol, Los Angeles, CA USA

来源：

关键词：

D O I：

10.1182/blood.V120.21.728.728

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

728

引用

页数：2